Navigation Links
Medarex Presents Preclinical Data Demonstrating Potent Anti-Tumor,Activity of Anti-CD19 and Anti-CD70 Antibody-Drug Conjugates in,Cancer Animal Models

afety profiles in larger animals at dose levels which are in excess of an efficacious dose determined in the xenograft models.

"Antibody-drug conjugates exploit the specificity of antibodies and the potency of cytotoxic agents to destroy cancer cells," said Nils Lonberg, PhD, Senior Vice President and Science Director at Medarex. "We believe that the anti-tumor activity from these preclinical antibody-drug conjugate studies is quite compelling, and we look forward to fully exploring the safety and therapeutic activity and application of these programs in future clinical trials."

About Medarex

Medarex is a biopharmaceutical company focused on the discovery, development and potential commercialization of fully human antibody-based therapeutics to treat life-threatening and debilitating diseases, including cancer, inflammation, autoimmune disorders and infectious diseases. Medarex applies its UltiMAb(R) technology and product development and clinical manufacturing experience to generate, support and potentially commercialize a broad range of fully human antibody product candidates for itself and its partners. More than 30 of these therapeutic product candidates derived from Medarex technology are in human clinical testing or have had INDs submitted for such trials, with six of the most advanced product candidates currently in Phase III clinical trials. Medarex is committed to building value by developing a diverse pipeline of antibody products to address the world's unmet healthcare needs. For more information about Medarex, visit its website at www.medarex.com.

Medarex Statement on Cautionary Factors

Except for the historical information presented herein, matters discussed herein may constitute forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements exp
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
2. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
3. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
4. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
5. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
6. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
7. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
8. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
9. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
10. DiObex Presents Phase 2a Data of DIO-902 Demonstrating Trends of Improved Glycemic Control and Significant Reductions of LDL-Cholesterol and C-Reactive Protein
11. BioCryst Presents Phase I Peramivir Data at the Options for the Control of Influenza Conference
Post Your Comments:
(Date:7/30/2014)... -- DigiPath, Inc. (OTCBB and OTCQB: DIGP), a digital pathology ... and education markets, announced today that has been no ... disclosed or, to its knowledge, any other reason to ... "We have noticed unusual price and volume increases for ... Steve Barbee , CEO of DigiPath. "While we ...
(Date:7/30/2014)... and NEW YORK , ... ACCP), a developer of new products for oncology supportive ... MuGard ® , has been featured in an article ... Mucositis Symptoms in Head and Neck Cancers."  Dr. ... provides insight on the growing demand seen in the ...
(Date:7/30/2014)... -- Hospira, Inc. (NYSE: HSP ), the ... technologies, today reported results for the second quarter ... quarter were $1.1 billion and adjusted* diluted earnings ... items as described later in this press release ... Accepted Accounting Principles (GAAP) basis, second-quarter 2014 diluted ...
Breaking Medicine Technology:DigiPath No New Corporate Developments 2Access Pharmaceuticals Featured On OncLive.com 2Access Pharmaceuticals Featured On OncLive.com 3Hospira Reports Second-Quarter 2014 Results 2Hospira Reports Second-Quarter 2014 Results 3Hospira Reports Second-Quarter 2014 Results 4Hospira Reports Second-Quarter 2014 Results 5Hospira Reports Second-Quarter 2014 Results 6Hospira Reports Second-Quarter 2014 Results 7Hospira Reports Second-Quarter 2014 Results 8Hospira Reports Second-Quarter 2014 Results 9Hospira Reports Second-Quarter 2014 Results 10Hospira Reports Second-Quarter 2014 Results 11Hospira Reports Second-Quarter 2014 Results 12Hospira Reports Second-Quarter 2014 Results 13Hospira Reports Second-Quarter 2014 Results 14Hospira Reports Second-Quarter 2014 Results 15Hospira Reports Second-Quarter 2014 Results 16Hospira Reports Second-Quarter 2014 Results 17Hospira Reports Second-Quarter 2014 Results 18Hospira Reports Second-Quarter 2014 Results 19Hospira Reports Second-Quarter 2014 Results 20Hospira Reports Second-Quarter 2014 Results 21Hospira Reports Second-Quarter 2014 Results 22Hospira Reports Second-Quarter 2014 Results 23Hospira Reports Second-Quarter 2014 Results 24Hospira Reports Second-Quarter 2014 Results 25Hospira Reports Second-Quarter 2014 Results 26Hospira Reports Second-Quarter 2014 Results 27Hospira Reports Second-Quarter 2014 Results 28Hospira Reports Second-Quarter 2014 Results 29Hospira Reports Second-Quarter 2014 Results 30Hospira Reports Second-Quarter 2014 Results 31
... 26, 2012 Interventional Spine, Inc. today announced ... Body Fusion Device. (Logo: ... Access Instrument, which provides unparalleled percutaneous access to ... an integral part of Interventional Spine,s revolutionary PerX360 ...
... VIEW, Calif., Jan. 25, 2012  IRIDEX Corporation (Nasdaq: ... clinical study evaluating the use of IRIDEX, MicroPulse ... effectiveness with patients diagnosed with central serous chorioretinopathy ... is superior to anti-VEGF injections for CSC, also ...
Cached Medicine Technology:Interventional Spine, Inc. Announces FDA Clearance of its Opticage™ Expandable Interbody for Treatment of Degenerative Disc Disease 2IRIDEX MicroPulse™ Laser Therapy Enhances Visual Function in Patients with Central Serous Chorioretinopathy (CSC) 2IRIDEX MicroPulse™ Laser Therapy Enhances Visual Function in Patients with Central Serous Chorioretinopathy (CSC) 3
(Date:7/30/2014)... 2014 Conducting Advanced Root Cause ... Skills and Innovative Techniques to Improve the Quality ... FDAnews**, Sept. 17-18, 2014 – Raleigh, NC, ... reason for 483 observations since 1997. , The ... successful CAPA program has never been more important. ...
(Date:7/30/2014)... 30, 2014 Good Neighbor Community ... an upcoming episode of Innovations with Ed Begley ... Dates and show times TBA. , In this ... Community Services’ vision to redefine the traditional approach ... dynamic services. Through passion, innovation, determination, excellence, and ...
(Date:7/30/2014)... (PRWEB) July 30, 2014 SF Cable, ... at the lowest prices on the internet with guaranteed ... in two lengths and two colors. These lightning cords ... , The high quality SF Cable Lightning ... with digital signal delivering faster charging and syncing. Compatible ...
(Date:7/30/2014)... Hamilton Facial Plastic Surgery ... Carmel office on July 30th. After months of planning, ... to the state-of-the-art suite, located only steps away from ... allow for one-on-one patient comfort, shorter wait times, and ... Dr. Hamilton’s new office-suite will continue to provide the ...
(Date:7/30/2014)... ... ... ... , UCLA researchers interviewed people with diverticulitis ... week in the peer-reviewed journal Quality of Life Research , a UCLA team led by Dr. Brennan Spiegel interviewed patients in ...
Breaking Medicine News(10 mins):Health News:FDAnews Workshop: Conducting Advanced Root Cause Analysis CAPA Investigations, Sept. 17-18, 2014, Raleigh, NC 2Health News:FDAnews Workshop: Conducting Advanced Root Cause Analysis CAPA Investigations, Sept. 17-18, 2014, Raleigh, NC 3Health News:FDAnews Workshop: Conducting Advanced Root Cause Analysis CAPA Investigations, Sept. 17-18, 2014, Raleigh, NC 4Health News:Good Neighbor Community Services to be Featured in an Upcoming Episode of Innovations With Ed Begley, Jr. 2Health News:SF Cable Delivers Certified Lightning Cable in Multiple Sizes and Colors 2Health News:Hamilton Facial Plastic Surgery Opens New Carmel Office 2Health News:Diverticulitis patients reveal psychological, physical symptoms long after acute attacks 2Health News:Diverticulitis patients reveal psychological, physical symptoms long after acute attacks 3
... imaging technique developed at the University of Illinois ... neurological problems, such as// Chiari malformations, hydrocephalus and ... through a $1.4 million National Institutes of Health ... which draws on bioengineering, radiology and neurosurgery, will ...
... cells, seem to be obstinate, as scientists have discovered, ... a result, they are extremely// difficult to annihilate. In ... stem cells, warn researchers from the University of California, ... this tendency of stem cells that get radiation resistant ...
... stay fit, old people especially those who are 70 and ... indulge// in brain exercises, to enhance their cognitive abilities to ... ,Previous insights have indicated the benefits of engaging ... led by Sherry Willis, a human-development professor at Penn State ...
... of brain fever has killed 35 children in three months ... ,After Japanese encephalitis and viral encephalitis killed at least ... mysterious but fatal virus is prowling the region claiming children ... large so we are actually at a loss as to ...
... from olive oil, glycerine and egg yolk would ... surgery.// ,The journal of Catheterization and Cardiovascular ... led by Michael Savage, M.D., director, Cardiac Catheterization ... ,The mixture is not swallowed, Dr. Savage explains. ...
... Pradesh legislative assembly will undergo tests to screen for AIDS.// ... R. Suresh Reddy, Health Minister K. Rosaiah and leaders of ... camp held for legislators in the assembly premises. , ... should undergo the tests to set an example for others. ...
Cached Medicine News:Health News:New MRI Technique Measures Intracranial Pressure in Brain Disorder 2Health News:Olive Oil Emulsions Prevent Cardiac Bypass Surgery 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: